6-methyl-N-phenethyl-[1,3,5]triazine-2,4-diamine | 30253-52-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 6-methyl-N-phenethyl-[1,3,5]triazine-2,4-diamine
• 英文别名: 6-methyl-N²-phenethyl-[1,3,5]triazine-2,4-diyldiamine；6-Methyl-N²-phenaethyl-[1,3,5]triazin-2,4-diyldiamin；2-Amino-4-(β-phenaethylamino)-6-methyl-s-triazin；6-methyl-2-N-(2-phenylethyl)-1,3,5-triazine-2,4-diamine
• CAS: 30253-52-2
• 化学式: C₁₂H₁₅N₅
• 分子量: 229.285
• InChiKey: JIUACSLHMARMKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-苯乙胺盐酸盐 生成 6-methyl-N-phenethyl-[1,3,5]triazine-2,4-diamine
  参考文献：
  名称：

  Hypoglycemic Agents. I.¹ Chemical Properties of β-Phenethylbiguanide.² A New Hypoglycemic Agent³

  摘要：

  DOI：

  10.1021/ja01518a052

文献信息

• NOVEL DIHYDROTRIAZINE DERIVATIVE
  申请人：Maeda Shirou

  公开号：US20110207926A1

  公开（公告）日：2011-08-25

  A compound represented by formula (1), a tautomer thereof, or a salt of the compound or tautomer, which is useful as a bactericide/disinfectant. In the formula, R 1 represents a hydrogen atom, an optionally substituted alkyl group or the like, R 2 represents a hydrogen atom or an optionally substituted alkyl group, or alternatively R 1 and R 2 may combine together with an adjacent nitrogen atom to form an optionally substituted nitrogen-containing heterocyclic group; R 4 represents a hydrogen atom or an optionally substituted alkyl group; R 3 represents an optionally substituted alkyl group; and R 5 and R 6 each represents a hydrogen atom or a methyl group, excluding a compound wherein both R 2 and R 4 represent a hydrogen atom and a compound wherein both R 1 and R 4 represent a hydrogen atom are excluded.

  化合物以式（1）表示，其互变异构体或盐，用作杀菌剂/消毒剂。在公式中，R1表示氢原子，可选取代的烷基或类似物，R2表示氢原子或可选取代的烷基，或者R1和R2可以与相邻的氮原子结合形成可选取代的含氮杂环基团；R4表示氢原子或可选取代的烷基；R3表示可选取代的烷基；R5和R6各表示氢原子或甲基，但排除R2和R4均表示氢原子的化合物和R1和R4均表示氢原子的化合物。
• Compositions and Methods for Treating Metabolic Disorders
  申请人：Elcelyx Therapeutics, Inc.

  公开号：US20140193498A1

  公开（公告）日：2014-07-10

  Compositions and methods for improving the pharmacokinetics and reducing the risk of adverse events resulting from biguanide compound administration are provided, comprising administering delayed release formulations of such compounds having a lag phase release.

  本发明提供了用于改善双胍类化合物的药代动力学并减少由其使用导致的不良事件风险的组合物和方法，包括给予延迟释放配方的这种化合物，其具有滞后释放阶段。
• Biguanide compositions and methods of treating metabolic disorders
  申请人：Elcelyx Therapeutics, Inc.

  公开号：US10028923B2

  公开（公告）日：2018-07-24

  Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

  本文提供了通过施用包含双胍类或相关杂环化合物（如二甲双胍）的组合物来治疗某些疾病（包括糖尿病、肥胖症和其他代谢性疾病、失调或病症）的方法。本文还提供了双胍类或相关杂环化合物组合物及其用于本发明方法的制备方法。本文还提供了包含二甲双胍及其盐类的组合物和使用方法。
• Compositions and methods for treating metabolic disorders
  申请人：Elcelyx Therapeutics, Inc.

  公开号：US10201511B2

  公开（公告）日：2019-02-12

  Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

  本发明提供了改善双胍类化合物的胃肠道耐受性以及治疗代谢紊乱和/或使有需要的患者，特别是双胍类化合物治疗禁忌症患者减轻体重的方法，包括针对小肠施用包括二甲双胍在内的此类双胍类化合物的缓释制剂。
• BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS
  申请人：Anji Pharma (US) LLC

  公开号：EP2800561B1

  公开（公告）日：2020-08-19